Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

A Phase I Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses) and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib, cisplatin and radiation in the locally advanced squamous cell carcinomas of the head and neck (SCCHN)patient population.

Study Overview

• Status: Withdrawn
• Conditions: Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
• Intervention / Treatment: Drug: sorafenib; Drug: sorafenib; Drug: sorafenib and cisplatin; Drug: sorafenib and cisplatin; Drug: sorafenib and cisplatin

Detailed Description

Squamous cell carcinoma of the head and neck is a relatively common malignancy in both Canada and the United States. Despite advancements made with the demonstration of improved outcomes for concurrent platinum based chemotherapy with radical radiation in locally advanced SCCHN, approximately 50% of cases will recur. The current treatment of locoregionally recurrent/metastatic SCCHN is palliative in intent, with a median survival in this population of 6-8 months. Thus improvements to the current backbone treatment of locally advanced SCCHN, that is platinum based chemotherapy with radical radiation, are desperately needed.

This is a non-randomized, open-label, phase I dose escalation trial of neoadjuvant Sorafenib and concurrent Sorafenib, Cisplatin and radiation in locally advanced squamous cell carcinomas of the head and neck (SCCHN).

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • BC Cancer Agency - Vancouver Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Inclusion Criteria: Treatment Group 1 (Cohorts 1 & 2) - Radiation and Sorafenib Only.

1. Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Histological or cytological confirmation is required. The disease must be considered to be potentially curable with radiation only.
2. Stage III or IV disease (UICC/AJCC classification, 6th edition)
3. Age ≥18
4. Patients for whom concurrent cisplatinum is contraindicated due to poor patient tolerance (significant weight loss > 10% of body weight, mild renal dysfunction, ototoxicity, neuropathy, or age >70) yet deemed fit for radical radiation.
5. Signed written consent.
6. Availability for follow-up after treatment.
7. If the patient is fertile he/she is aware of the risk of becoming pregnant or fathering children and will use adequate contraception (oral contraception, IUD, diaphragm and spermicide or male condom and spermicide) throughout therapy and for at least 2 weeks after therapy.
8. Life expectancy greater than 6 months

Inclusion Criteria: Treatment group 2 (Cohorts 3 to 5) - Radiation, Sorafenib and Cisplatin.

1. Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Histological or cytological confirmation is required. The disease must be considered to be potentially curable by combined chemoradiation.
2. Stage III or IV disease (UICC/AJCC classification, 6th edition)
3. Age ≥18.
4. Signed written consent.
5. Availability for follow-up after treatment.
6. If the patient is fertile, he/she is aware of the risk of becoming pregnant or fathering children and will use adequate contraception (oral contraception, IUD, diaphragm and spermicide or male condom and spermicide) throughout therapy and for at least 3 months after therapy.
7. Life expectancy greater than 6 months

Exclusion Criteria:

Treatment Group 1 (Cohorts 1 & 2) - Radiation and Sorafenib Only.

1. ECOG performance status 3 or 4
2. Absolute neutrophil count <1.0 X 109/L, platelet count <100 X 109/L or hemoglobin <90 g/L.
3. Serum bilirubin ≥1.5 times ULN or AST/ALT ≥ 2.5 times ULN.
4. Calculated creatinine clearance (Cockcroft-Gault) <40 mL/min. For patients in whom the calculated creatinine clearance is borderline, GFR may be estimated by nuclear renogram with the creatinine clearance ≥ 40 mL/min to be eligible.
5. Uncontrolled hypertension despite adequate anti-hypertensive medications
6. Bleeding diathesis
7. Significant inter-current illness that will interfere with the radiation therapy during the trial such as HIV infection, pulmonary compromise, active significant alcohol abuse, active infection or febrile illness
8. Any history of myocardial infarction, congestive heart failure (NY Heart Association Class 3 or 4), any history of ventricular arrhythmias, angina or active coronary heart disease within 6 months.
9. Primary cancers of the nasal and paranasal cavities, and of the nasopharynx.
10. Evidence of distant metastases. If based on the best available clinical evidence the investigator wishes to enroll the subject on trial, discussion and documentation with one of the principal investigators is required.
11. Weight loss greater than 25% of usual body weight in the 3 months preceding trial entry.
12. High risk for poor compliance with therapy or follow-up as assessed by investigator.
13. Pregnant or lactating women.
14. Prior radiation therapy to greater than 30% of the bone marrow
15. Prior experimental therapy for cancer within 30 days of entering the trial.
16. Prior radiation for head and neck cancer.
17. Patients with prior cancers, except: those diagnosed more than five years ago with no evidence of disease recurrence and a clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix. However, any patient with previous invasive breast cancer, prostate cancer or melanoma is excluded.

Exclusion Criteria: Treatment group 2 (Cohorts 3 to 5) - Radiation, Sorafenib and Cisplatin.

1. ECOG performance status 3 or 4
2. Absolute neutrophil count <1.0 X 109/L, platelet count <100 X 109/L or hemoglobin <90 g/L.
3. Serum bilirubin ≥1.5 times ULN or AST/ALT ≥ 2.5 times ULN.
4. Calculated creatinine clearance (Cockcroft-Gault) <55 mL/min. For patients in whom the calculated creatinine clearance is borderline, GFR may be estimated by nuclear renogram with the creatinine clearance ≥ 55 mL/min to be eligible.
5. Uncontrolled hypertension despite adequate anti-hypertensive medications
6. Bleeding diathesis
7. Significant inter-current illness that will interfere with the chemotherapy or radiation therapy during the trial such as HIV infection, cardiac insufficiency, pulmonary compromise, active significant alcohol abuse, active infection or febrile illness,
8. Any history of myocardial infarction, any history of ventricular arrhythmias, angina or active coronary heart disease within 6 months. Significant cardiac disease resulting in an inability to tolerate the intravenous fluid load as required for administration of cisplatin.
9. Primary cancers of the nasal and paranasal cavities, and of the nasopharynx.
10. Evidence of distant metastases. If based on the best available clinical evidence the investigator wishes to enroll the subject on trial, discussion and documentation with one of the principal investigators is required.
11. Symptomatic peripheral neuropathy ≥ grade 2.
12. Clinically significant sensori-neural hearing impairment which may be exacerbated by cisplatin (audiometric abnormalities without corresponding clinical hearing impairment will not be grounds for exclusion)
13. Weight loss greater than 20% of usual body weight in the 3 months preceding trial entry.
14. High risk for poor compliance with therapy or follow-up as assessed by investigator.
15. Pregnant or lactating women.
16. Prior radiation therapy to greater than 30% of the bone marrow
17. Prior experimental therapy for cancer within 30 days of entering the trial.
18. Prior radiation for head and neck cancer.
19. Patients with prior cancers, except: those diagnosed more than five years ago with no evidence of disease recurrence and a clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix. However, any patient with previous invasive breast cancer, prostate cancer or melanoma is excluded.

Study Plan

How is the study designed?

Design Details

• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Group 1: Cohort 1; Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation	Drug: sorafenib; Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation; Drug: sorafenib; o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
Experimental: Treatment Group 1: sorafenib and radiation: Cohort 2; Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation	Drug: sorafenib; Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation; Drug: sorafenib; o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
Experimental: Treatment Group 2: Cohort 3; Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7	Drug: sorafenib and cisplatin; Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7; Drug: sorafenib and cisplatin; o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7; Drug: sorafenib and cisplatin; Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
Experimental: Treatment Group 2: Cohort 4; o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7	Drug: sorafenib and cisplatin; Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7; Drug: sorafenib and cisplatin; o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7; Drug: sorafenib and cisplatin; Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
Experimental: Treatment Group 2:Cohort 5; Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7	Drug: sorafenib and cisplatin; Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7; Drug: sorafenib and cisplatin; o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7; Drug: sorafenib and cisplatin; Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To assess the safety of neoadjuvant BAY 43-9006 (sorafenib) and concurrent BAY 43-9006 with radiation in a cohort of SCCHN	ongoing

Secondary Outcome Measures

Outcome Measure	Time Frame
MTD Maximal tolerated dose	ongoing

Collaborators and Investigators

• Sponsor: British Columbia Cancer Agency

Study record dates

Study Registration Dates

• First Submitted: February 14, 2008
• First Submitted That Met QC Criteria: February 22, 2008
• First Posted (Estimate): March 3, 2008

Study Record Updates

• Last Update Posted (Estimate): July 20, 2016
• Last Update Submitted That Met QC Criteria: July 18, 2016
• Last Verified: November 1, 2010

More Information

Terms related to this study

• Keywords: head and neck; squamous cell carcinoma; Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Head and Neck Neoplasms; Neoplasms, Squamous Cell; Carcinoma; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Cisplatin; Sorafenib
• Other Study ID Numbers: OZM-003